Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis

Zahava Vadasz; Yair Goldeberg; Katty Halasz; Itzhak Rosner; Guido Valesini; Fabrizio Conti; Carlo Perricone; Zev Sthoeger; Shira Rosenberg Bezalel; Athanasios G. Tzioufas; Nancy Agmon Levin; Yehuda Shoenfeld; Elias Toubi

doi:10.1016/j.clim.2016.02.004

Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis

Zahava Vadasz, Yair Goldeberg, Katty Halasz, Itzhak Rosner, Guido Valesini, Fabrizio Conti, Carlo Perricone, Zev Sthoeger, Shira Rosenberg Bezalel, Athanasios G. Tzioufas, Nancy Agmon Levin, Yehuda Shoenfeld, Elias Toubi

Department of Statistics

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: B cell receptor (BCR) -mediated signals are enhanced when CD72 expression is deficient on B cells in autoimmune diseases. The significance of soluble CD72 (sCD72) has not been elucidated. Methods: Soluble CD72 was analyzed in the serum of 159 SLE patients, 40 rheumatoid arthritis (RA) patients, and 100 healthy individuals. Correlations between sCD72 and SLE disease activity (SLEDAI) were assessed. Results: Soluble CD72 was found increased in SLE patients, when compared to both RA patients and healthy individuals (20.2 ± 1.2 ng/ml; 10.6 ± 4.6 ng/ml and 7.2 ± 3.3 ng/ml; p < 0.001). Soluble CD72 level was significantly higher in SLE patients with renal involvement than in patients without (31.8 ± 2.3 ng/ml vs 13.9 ± 0.9 ng/ml; p < 0.001) and also with the presence of auto-antibodies. Conclusion: Soluble CD72 is significantly increased in SLE patients mainly in those with renal involvement. Increased sCD72 may become a potential biomarker for renal involvement in SLE.

Original language	English
Pages (from-to)	114-118
Number of pages	5
Journal	Clinical Immunology
Volume	164
DOIs	https://doi.org/10.1016/j.clim.2016.02.004
State	Published - 1 Mar 2016

Bibliographical note

Publisher Copyright:
© 2015 .

Keywords

Anti-cardiolipin antibody
Anti-dsDNA antibody
Nephritis
SLE
SLEDAI
Soluble CD72

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.clim.2016.02.004

Cite this

Vadasz, Z., Goldeberg, Y., Halasz, K., Rosner, I., Valesini, G., Conti, F., Perricone, C., Sthoeger, Z., Bezalel, S. R., Tzioufas, A. G., Levin, N. A., Shoenfeld, Y., & Toubi, E. (2016). Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis. Clinical Immunology, 164, 114-118. https://doi.org/10.1016/j.clim.2016.02.004

@article{ce6f1e74616e4fab877047f3dabc9c8e,

title = "Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis",

abstract = "Introduction: B cell receptor (BCR) -mediated signals are enhanced when CD72 expression is deficient on B cells in autoimmune diseases. The significance of soluble CD72 (sCD72) has not been elucidated. Methods: Soluble CD72 was analyzed in the serum of 159 SLE patients, 40 rheumatoid arthritis (RA) patients, and 100 healthy individuals. Correlations between sCD72 and SLE disease activity (SLEDAI) were assessed. Results: Soluble CD72 was found increased in SLE patients, when compared to both RA patients and healthy individuals (20.2 ± 1.2 ng/ml; 10.6 ± 4.6 ng/ml and 7.2 ± 3.3 ng/ml; p < 0.001). Soluble CD72 level was significantly higher in SLE patients with renal involvement than in patients without (31.8 ± 2.3 ng/ml vs 13.9 ± 0.9 ng/ml; p < 0.001) and also with the presence of auto-antibodies. Conclusion: Soluble CD72 is significantly increased in SLE patients mainly in those with renal involvement. Increased sCD72 may become a potential biomarker for renal involvement in SLE.",

keywords = "Anti-cardiolipin antibody, Anti-dsDNA antibody, Nephritis, SLE, SLEDAI, Soluble CD72",

author = "Zahava Vadasz and Yair Goldeberg and Katty Halasz and Itzhak Rosner and Guido Valesini and Fabrizio Conti and Carlo Perricone and Zev Sthoeger and Bezalel, {Shira Rosenberg} and Tzioufas, {Athanasios G.} and Levin, {Nancy Agmon} and Yehuda Shoenfeld and Elias Toubi",

note = "Publisher Copyright: {\textcopyright} 2015 .",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.clim.2016.02.004",

language = "English",

volume = "164",

pages = "114--118",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis

AU - Vadasz, Zahava

AU - Goldeberg, Yair

AU - Halasz, Katty

AU - Rosner, Itzhak

AU - Valesini, Guido

AU - Conti, Fabrizio

AU - Perricone, Carlo

AU - Sthoeger, Zev

AU - Bezalel, Shira Rosenberg

AU - Tzioufas, Athanasios G.

AU - Levin, Nancy Agmon

AU - Shoenfeld, Yehuda

AU - Toubi, Elias

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Introduction: B cell receptor (BCR) -mediated signals are enhanced when CD72 expression is deficient on B cells in autoimmune diseases. The significance of soluble CD72 (sCD72) has not been elucidated. Methods: Soluble CD72 was analyzed in the serum of 159 SLE patients, 40 rheumatoid arthritis (RA) patients, and 100 healthy individuals. Correlations between sCD72 and SLE disease activity (SLEDAI) were assessed. Results: Soluble CD72 was found increased in SLE patients, when compared to both RA patients and healthy individuals (20.2 ± 1.2 ng/ml; 10.6 ± 4.6 ng/ml and 7.2 ± 3.3 ng/ml; p < 0.001). Soluble CD72 level was significantly higher in SLE patients with renal involvement than in patients without (31.8 ± 2.3 ng/ml vs 13.9 ± 0.9 ng/ml; p < 0.001) and also with the presence of auto-antibodies. Conclusion: Soluble CD72 is significantly increased in SLE patients mainly in those with renal involvement. Increased sCD72 may become a potential biomarker for renal involvement in SLE.

AB - Introduction: B cell receptor (BCR) -mediated signals are enhanced when CD72 expression is deficient on B cells in autoimmune diseases. The significance of soluble CD72 (sCD72) has not been elucidated. Methods: Soluble CD72 was analyzed in the serum of 159 SLE patients, 40 rheumatoid arthritis (RA) patients, and 100 healthy individuals. Correlations between sCD72 and SLE disease activity (SLEDAI) were assessed. Results: Soluble CD72 was found increased in SLE patients, when compared to both RA patients and healthy individuals (20.2 ± 1.2 ng/ml; 10.6 ± 4.6 ng/ml and 7.2 ± 3.3 ng/ml; p < 0.001). Soluble CD72 level was significantly higher in SLE patients with renal involvement than in patients without (31.8 ± 2.3 ng/ml vs 13.9 ± 0.9 ng/ml; p < 0.001) and also with the presence of auto-antibodies. Conclusion: Soluble CD72 is significantly increased in SLE patients mainly in those with renal involvement. Increased sCD72 may become a potential biomarker for renal involvement in SLE.

KW - Anti-cardiolipin antibody

KW - Anti-dsDNA antibody

KW - Nephritis

KW - SLE

KW - SLEDAI

KW - Soluble CD72

UR - http://www.scopus.com/inward/record.url?scp=84958539961&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2016.02.004

DO - 10.1016/j.clim.2016.02.004

M3 - Article

C2 - 26883681

AN - SCOPUS:84958539961

SN - 1521-6616

VL - 164

SP - 114

EP - 118

JO - Clinical Immunology

JF - Clinical Immunology

ER -

Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this